BML Delivers Strong Q3 Earnings and Raises Full-Year Outlook While Maintaining Dividend Plan

BML ( (JP:4694) ) has shared an update.

BML reported solid growth for the third quarter of fiscal 2025, with net sales rising 5.4% year-on-year to ¥114.5 billion and profit attributable to owners of the parent climbing 24.6% to ¥6.6 billion, reflecting improved profitability and higher earnings per share. Despite a slight decline in total assets and equity ratio compared with the end of the previous fiscal year, the company maintained a robust financial position and confirmed its full-year dividend forecast of ¥120 per share, while revising its full-year earnings outlook upward to project increases in sales, operating profit and net income, signaling continued earnings momentum and shareholder returns stability.

The most recent analyst rating on (JP:4694) stock is a Hold with a Yen4233.00 price target. To see the full list of analyst forecasts on BML stock, see the JP:4694 Stock Forecast page.

More about BML

BML, Inc. is a Japan-based company listed on the Tokyo Stock Exchange that operates in the medical testing and diagnostics services industry, providing clinical laboratory testing and related services to healthcare providers across Japan. Its business is focused on stable, recurring demand from the healthcare sector, positioning it as a key player in the domestic medical testing market.

Average Trading Volume: 65,891

Technical Sentiment Signal: Buy

Current Market Cap: Yen148.6B

Learn more about 4694 stock on TipRanks’ Stock Analysis page.